{Reference Type}: Journal Article
{Title}: Shoring Up Osteoporosis Management: A Fresh Start?
{Author}: Furr N;Ulmer A;Cardon B;
{Journal}: J Am Board Fam Med
{Volume}: 37
{Issue}: 3
{Year}: 2024 May-Jun
{Factor}: 2.395
{DOI}: 10.3122/jabfm.2024.240060R0
{Abstract}: Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.